A Data Driven Approach to Profile Potential SARS-CoV-2 Drug Interactions Using TylerADE (Preprint)
UNSTRUCTURED We use a data driven approach on a cleaned FAERS database to determine the adverse drug reaction severity of several covid-19 drug combinations and further investigate their safety for vulnerable populations such as individuals 65 years and older. Our key findings include 1. hydroxychloroquine/chloroquine is associated with increased adverse drug event severity versus other drug combinations already not recommended by NIH treatment guidelines, 2. hydroxychloroquine/azithromycin is associated with lower adverse drug event severity among older populations and 3. lopinavir/ritonavir has lower adverse reaction severity among toddlers. While this approach does not consider drug efficacy, it can help prioritize clinical trials for drug combinations by focusing on those combinations with decreased adverse drug reaction severity.